Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Q-linea AB ( (SE:QLINEA) ) has shared an announcement.
Q-linea AB has made significant progress in its 2025 plan, with 14 ASTar instrument placements year-to-date and a target of 30-40 placements by the end of 2025. The company is expanding its commercial reach across EMEA and the US, with notable adoption in Italy and ongoing evaluations in multiple countries. A successful capital raise and increasing interest in the ASTar platform highlight its growing market differentiation, as evidenced by independent research and clinical feedback showing improved treatment times.
More about Q-linea AB
Q-linea AB is a company operating in the medical technology industry, focusing on rapid antimicrobial susceptibility testing (AST) solutions. Their primary product, ASTar, is designed to provide faster and actionable results for microbiology laboratories, with a market focus on expanding its presence across Europe, the Middle East, and the United States.
Average Trading Volume: 28,212,362
Current Market Cap: SEK322.8M
See more data about QLINEA stock on TipRanks’ Stock Analysis page.